Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 5
2018 5
2019 5
2020 2
2021 3
2022 3
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
Yamauchi R, Ito T, Yoshio S, Yamamoto T, Mizuno K, Ishigami M, Kawashima H, Yasuda S, Shimose S, Iwamoto H, Yamazoe T, Mori T, Kakazu E, Kawaguchi T, Toyoda H, Kanto T. Yamauchi R, et al. Among authors: mizuno k. J Gastroenterol. 2023 Jun;58(6):565-574. doi: 10.1007/s00535-023-01985-w. Epub 2023 Mar 30. J Gastroenterol. 2023. PMID: 36991155
Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitis.
Yamamoto T, Mizuno K, Ito T, Yokoyama S, Yamamoto K, Imai N, Ishizu Y, Honda T, Ishikawa T, Kanamori A, Yasuda S, Toyoda H, Yokota K, Hase T, Nishio N, Maeda O, Ishii M, Sone M, Ando Y, Akiyama M, Ishigami M, Kawashima H. Yamamoto T, et al. Among authors: mizuno k. Invest New Drugs. 2023 Jun;41(3):512-521. doi: 10.1007/s10637-023-01366-3. Epub 2023 May 12. Invest New Drugs. 2023. PMID: 37171720
Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
Yamamoto T, Ito T, Hase T, Ishigami M, Mizuno K, Yamamoto K, Imai N, Ishizu Y, Honda T, Shibata H, Hatta T, Yogo N, Yasuda S, Toyoda H, Abe T, Kawashima H, Hashimoto N, Fujishiro M. Yamamoto T, et al. Among authors: mizuno k. Cancer Invest. 2022 Feb;40(2):189-198. doi: 10.1080/07357907.2021.1994586. Epub 2021 Nov 29. Cancer Invest. 2022. PMID: 34658277
Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies.
Ito T, Ishigami M, Yamamoto T, Mizuno K, Yamamoto K, Imai N, Ishizu Y, Honda T, Kawashima H, Yasuda S, Toyoda H, Yokota K, Hase T, Nishio N, Maeda O, Kato M, Hashimoto N, Hibi H, Kodera Y, Sone M, Ando Y, Akiyama M, Shimoyama Y, Fujishiro M. Ito T, et al. Among authors: mizuno k. Hepatol Int. 2021 Oct;15(5):1278-1287. doi: 10.1007/s12072-021-10238-y. Epub 2021 Aug 9. Hepatol Int. 2021. PMID: 34373964
A case of antiprogrammed death-ligand 1 antibody-induced multisystem immune-related adverse events with pancreatitis and steroid-resistant sclerosing cholangitis.
Yamamoto T, Ito T, Mizuno K, Shinya Y, Yamamoto K, Imai N, Ishizu Y, Honda T, Kawashima H, Matsui T, Hase T, Hashimoto N, Ishigami M. Yamamoto T, et al. Among authors: mizuno k. J Dig Dis. 2022 Jul;23(7):404-409. doi: 10.1111/1751-2980.13122. J Dig Dis. 2022. PMID: 35962644 No abstract available.
23 results